TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

Federico Rojo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.